AI-empowered Pipeline-in-a-drug Option: Insilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders and Aging
PR Newswire
CAMBRIDGE, Mass., Aug. 5, 2026
As a dual-purpose, potential first-in-class, "pipeline-in-a-drug" candidate, ISM9077 provides an innovative solution for ocular diseases, inflammatory disorders, and the fundamental aging process.ISM9077 was designed, evaluated and optimized utilizing Chemistry42's integrated generative AI models, marking Insilico's 32nd PCC nominated since 2021.In preclinical studies, ISM9077 outperformed current therapies in dry AMD, uveitis and dry eye models, while demonstrating a favorable safety profile represented by wide safety margin.Aside from the promising efficacy results, the candidate, with a novel target and a novel molecule structure driven by AI, also exhibits good permeability, excellent retinal tissue exposure, supporting novel delivery method potential (both oral and eye drop)CAMBRIDGE, Mass. , Aug. 5, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the nomination of ISM9077, the AI-empowered, potential first-in-class Target Y inhibitor with pipeline-in-a-drug potential, as a Preclinical Candidate (PCC) for the treatment of ocular diseases including dry Age-Related Macular Degeneration (dry AMD), uveitis, and dry eye disease. As the 32nd PCC nominated since 2021, ISM9077 boasts potent inhibition across species, excellent exposure and permeability traits, and a favorable safety profile in preclinical studies.
